SCYNEXIS (NASDAQ:SCYX) Shares Pass Above Fifty Day Moving Average of $1.56

Shares of SCYNEXIS, Inc. (NASDAQ:SCYX) passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $1.56 and traded as high as $1.79. SCYNEXIS shares last traded at $1.73, with a volume of 113,510 shares changing hands.

Analyst Ratings Changes

A number of research firms recently weighed in on SCYX. Cantor Fitzgerald reissued an “overweight” rating on shares of SCYNEXIS in a research note on Monday, April 1st. StockNews.com lowered SCYNEXIS from a “buy” rating to a “hold” rating in a research note on Monday, March 18th.

SCYNEXIS Stock Down 2.3 %

The firm has a market cap of $65.36 million, a price-to-earnings ratio of 1.31 and a beta of 1.49. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.26 and a current ratio of 6.26. The business’s 50-day moving average is $1.56 and its 200-day moving average is $1.73.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Decheng Capital LLC acquired a new stake in SCYNEXIS during the 4th quarter valued at $1,239,000. Kingdon Capital Management L.L.C. increased its stake in shares of SCYNEXIS by 19.2% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 2,237,048 shares of the company’s stock valued at $4,989,000 after buying an additional 359,900 shares in the last quarter. AMH Equity Ltd raised its holdings in shares of SCYNEXIS by 134.4% in the fourth quarter. AMH Equity Ltd now owns 550,400 shares of the company’s stock valued at $1,227,000 after buying an additional 315,612 shares during the last quarter. Acadian Asset Management LLC acquired a new position in SCYNEXIS during the 3rd quarter worth about $673,000. Finally, Avidity Partners Management LP grew its holdings in SCYNEXIS by 9.8% during the 4th quarter. Avidity Partners Management LP now owns 1,448,728 shares of the company’s stock worth $3,231,000 after acquiring an additional 129,284 shares during the last quarter. Institutional investors own 54.37% of the company’s stock.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.